Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
Background Cancer immunotherapy has evolved from interferon-alpha (IFNα) and interleukin-2 in the 1980s to CTLA-4 and PD-1/PD-L1 checkpoint inhibitors (CPIs), the latter highlighting the importance of enhancing T-cell functions. While the search for novel immunomodulatory pathways continues, combina...
Saved in:
| Main Authors: | Jeanne Cheung, Rafael Cubas, Zia Khan, Qian Gong, Marina Moskalenko, Huizhong Xiong, Qinglin Ou, Christine Pai, Ryan Rodriguez, Andrew C Chan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001439.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A conserved protein tyrosine phosphatase, PTPN-22, functions in diverse developmental processes in C. elegans.
by: Shaonil Binti, et al.
Published: (2024-08-01) -
The phosphatases TCPTP, PTPN22, and SHP1 play unique roles in T cell phosphotyrosine maintenance and feedback regulation of the TCR
by: Aurora Callahan, et al.
Published: (2025-07-01) -
Optimization of Lipoplexes Functionalized with a Sialic Acid Mimetic (F9-PEG) to Target the C1858T <i>PTPN22</i> Variant for Preclinical Assessment of a Novel Immunotherapy in Endocrine Autoimmunity
by: Simona Sennato, et al.
Published: (2025-05-01) -
Tyrosine Phosphatases in the HER2-Directed Motility of Ovarian Cancer Cells: Involvement of PTPN12, ERK5 and FAK
by: Emma Villa-Moruzzi
Published: (2011-01-01) -
The PTPN22 locus and rheumatoid arthritis: no evidence for an effect on risk independent of Arg620Trp.
by: Wan R Wan Taib, et al.
Published: (2010-10-01)